1 Day SNDA -0.26% DJIA 0.65% Russell 2K -1.03% Health Care/Life Sciences -1.12% ...

Merck MRK announced that the FDA has accepted its supplemental new drug application (sNDA) seeking approval of its oral HIF-2α inhibitor, Welireg (belzutifan), for a new indication. The sNDA is ...

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience. To access our Live RNS you must confirm you are a private ...

Buy SNDA near 20.28 target 26.36 stop loss @ 20.22 Details The technical summary data tells us to buy SNDA near 20.28 with an upside target of 26.36. This data also tells us to set a stop loss @ 20.22 ...

Positive interim data was reported from the ENERGY 1 trial and Expanded Access Program that featured a total of 5 infants and 1 child.

2020, Book Chapter: "In a time of increasing divisiveness in politics and society, there is a desperate need for leaders to bring people together and leverage the power of diversity and inclusion.

Johnson & Johnson announced the U.S. FDA approval of a supplemental New Drug Application for Spravato CIII nasal spray, making this innovative treatment the first and only monotherapy for adults ...

Scilex (SCLX) announced that it will be filing today of a Supplemental New Drug Application, SNDA, with the FDA for ELYXYB in acute pain indication. “We are well positioned to broaden the ELYXYB ...

The FDA is reviewing new vaccines for meningitis and chikungunya and therapies for Parkinson disease and PTSD. The FDA is reviewing the resubmitted NDA for SPN-830, an apomorphine infusion device for ...

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are ...